Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikael Hoffmann

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Maturitas|July 19, 2005
Changes in women's attitudes towards and use of hormone therapy after HERS and WHIMikael Hoffmann, Mats Hammar, Karin I Kjellgren, et al.
Menopause (New York, N.Y.)|May 24, 2007
Knowledge of reproductive physiology and hormone therapy in 53- to 54-year-old Swedish women: a population-based studyLotta Lindh-Astrand, Jan Brynhildsen, Mikael Hoffmann, et al.
Maturitas|December 14, 2004
Hormone replacement therapy in the menopause. Structure and content of risk talkMikael Hoffmann, Lotta Lindh-Astrand, Johan Ahlner, et al.
Maturitas|June 24, 2023
Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021Micaela Sundell, Jan Brynhildsen, Anna-Clara Spetz Holm, et al.
Journal of Hypertension|October 5, 2023
Reply to 'Examining the impact of E-health management on hypertension'Ulrika Andersson, Peter M Nilsson, Karin Kjellgren, et al.
Journal of Hypertension|November 17, 2022
PERson-centredness in Hypertension management using Information Technology: a randomized controlled trial in primary careUlrika Andersson, Peter M Nilsson, Karin Kjellgren, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 18, 2009
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceBrian Godman, Björn Wettermark, Mikael Hoffmann, et al.
European Journal of Clinical Pharmacology|May 14, 2024
Reliability and validity of the Swedish indicator 'Drugs that should be avoided in older people'-an appraisal of a set of potentially inappropriate medicationsNaldy Parodi López, Staffan A Svensson, Johan Lönnbro, et al.
Lakartidningen|August 16, 2005
[Inspra and the drug benefits board: What is the role of the drug committees?]Mikael Hoffmann, Rune Dahlqvist, Lars-Ake Levin, et al.
Maturitas|April 28, 2019
Use of hormone therapy (HT) among Swedish women with contraindications - A pharmacoepidemiological cohort studyLotta Lindh-Åstrand, Mikael Hoffmann, Mats Fredrikson, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Maturitas|July 19, 2005
Changes in women's attitudes towards and use of hormone therapy after HERS and WHIMikael Hoffmann, Mats Hammar, Karin I Kjellgren, et al.
Menopause (New York, N.Y.)|May 24, 2007
Knowledge of reproductive physiology and hormone therapy in 53- to 54-year-old Swedish women: a population-based studyLotta Lindh-Astrand, Jan Brynhildsen, Mikael Hoffmann, et al.
Maturitas|December 14, 2004
Hormone replacement therapy in the menopause. Structure and content of risk talkMikael Hoffmann, Lotta Lindh-Astrand, Johan Ahlner, et al.
Maturitas|June 24, 2023
Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021Micaela Sundell, Jan Brynhildsen, Anna-Clara Spetz Holm, et al.
Journal of Hypertension|October 5, 2023
Reply to 'Examining the impact of E-health management on hypertension'Ulrika Andersson, Peter M Nilsson, Karin Kjellgren, et al.
Journal of Hypertension|November 17, 2022
PERson-centredness in Hypertension management using Information Technology: a randomized controlled trial in primary careUlrika Andersson, Peter M Nilsson, Karin Kjellgren, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 18, 2009
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceBrian Godman, Björn Wettermark, Mikael Hoffmann, et al.
European Journal of Clinical Pharmacology|May 14, 2024
Reliability and validity of the Swedish indicator 'Drugs that should be avoided in older people'-an appraisal of a set of potentially inappropriate medicationsNaldy Parodi López, Staffan A Svensson, Johan Lönnbro, et al.
Lakartidningen|August 16, 2005
[Inspra and the drug benefits board: What is the role of the drug committees?]Mikael Hoffmann, Rune Dahlqvist, Lars-Ake Levin, et al.
Maturitas|April 28, 2019
Use of hormone therapy (HT) among Swedish women with contraindications - A pharmacoepidemiological cohort studyLotta Lindh-Åstrand, Mikael Hoffmann, Mats Fredrikson, et al.
Pageof 7